Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Taeryung KIM; Wonshik HAN; Min-Kyoon KIM; Jun-Woo LEE; Jisun KIM; Soo-Kyung AHN; Han-Byoel LEE; Hyeong-Gon MOON; Kyung-Hun LEE; Tae-Yong KIM; Sae-Won HAN; Seock-Ah IM; In-Ae PARK; Ju-Yeon KIM; Dong-Young NOH.
Journal of Breast Cancer ; : 16-21, 2015.
Artículo en Inglés | WPRIM | ID: wpr-173798

Documentos relacionados

  1. Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy.
  2. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
  3. Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer.
  4. Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications.
  5. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
  6. A reactive species reactions module for integration into genome-scale metabolic models for improved insights: Application to cancer.
  7. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
  8. Artificial intelligence: opportunities and challenges in the clinical applications of triple-negative breast cancer.
  9. Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer.
  10. Recent advances in metabolomics of triple negative breast cancer.